Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Joseph Feuerstein, M.D.

Co-Author

This page shows the publications co-authored by Joseph Feuerstein and Konstantinos Papamichail.
Connection Strength

1.494
  1. Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay. J Clin Med. 2020 Sep 02; 9(9).
    View in: PubMed
    Score: 0.229
  2. A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD. Inflamm Bowel Dis. 2020 06 18; 26(7):e59-e61.
    View in: PubMed
    Score: 0.226
  3. Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 04; 19(4):839-841.e2.
    View in: PubMed
    Score: 0.221
  4. Patients over Age 75 Are at Increased Risk of Emergency Department Visit and Hospitalization Following Colonoscopy. Dig Dis Sci. 2020 07; 65(7):1964-1970.
    View in: PubMed
    Score: 0.217
  5. Effect of Consent and Educational Adjuncts to Consent on Patient Perceptions About Colonoscopy. J Clin Gastroenterol. 2019 09; 53(8):e316-e321.
    View in: PubMed
    Score: 0.214
  6. Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private Practice. Dig Dis Sci. 2018 01; 63(1):36-45.
    View in: PubMed
    Score: 0.189
  7. Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Inflamm Bowel Dis. 2019 10 18; 25(11):e143-e145.
    View in: PubMed
    Score: 0.054
  8. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation. Clin Immunol. 2018 06; 191:59-62.
    View in: PubMed
    Score: 0.048
  9. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clin Immunol. 2019 09; 206:9-14.
    View in: PubMed
    Score: 0.048
  10. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 12 19; 24(1):191-197.
    View in: PubMed
    Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.